This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter C. Albertsen, MD; Dennis G. Fryback, PhD; Barry E. Storer, PhD; Thomas F. Kolon, MD; Judith Fine

JAMA. 1995;274(8):626-631.

Abstract
Objective.
—To determine age-specific, all-cause mortality, disease-specific mortality, and life expectancy for men aged 65 to 75 years who are treated only with immediate or delayed hormonal therapy for newly diagnosed, clinically localized prostate cancer.

Design.
—A population-based, retrospective cohort study.

Setting.
—Patient records were abstracted from 37 acute care hospitals and two Veterans Affairs medical centers in Connecticut. Original pathology slides were sent to a referee pathologist who was blinded to case outcomes.

Subjects.
—All men identified by the Connecticut Tumor Registry with clinically localized prostate cancer diagnosed in 1971 to 1976 who were aged 65 to 75 years at the time of diagnosis and were untreated or treated with immediate or delayed hormonal therapy.

Main Outcome Measures.
—Parametric proportional hazards models incorporating tumor histologic findings, comorbidity, and age at the time of diagnosis to compare cohort survival with that of men in the general population.

Results.
—After a mean follow-up of 15.5 years, the age-adjusted survival for men with Gleason score 2 to 4 tumors was not significantly different from that of the general population. Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival.

Conclusions.
—Compared with the general population, men aged 65 to 75 years with conservatively treated low-grade prostate cancer incur no loss of life expectancy. Men with higher-grade tumors (Gleason scores 5 to 10) experience a progressively increasing loss of life expectancy. Case series reports of survival/ mortality experienced by men with clinically localized prostate cancer that fail to control for age, tumor histologic features, and comorbidities risk significant bias.

(JAMA. 1995;274:626-631)

Author Affiliations
From the Division of Urology, Department of Surgery, University of Connecticut Health Center, Farmington (Drs Albertsen and Kolon); the Departments of Preventive Medicine and Biostatistics, University of Wisconsin—Madison (Drs Fryback and Storer); and the Yale Cancer Center, Yale University, New Haven, Conn (Ms Fine).

Footnotes
Reprint requests to the Division of Urology, Department of Surgery, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030-3955 (Dr Albertsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prospective Study of Determinants and Outcomes of Deferred Treatment or Watchful Waiting Among Men With Prostate Cancer in a Nationwide Cohort
Shappley et al.
JCO 2009;27:4980-4985.
ABSTRACT | FULL TEXT  

Evaluation of the clinimetric properties of the Early Inflammatory Arthritis--self-administered comorbidity questionnaire
Baron et al.
Rheumatology (Oxford) 2009;48:390-394.
ABSTRACT | FULL TEXT  

Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Lu-Yao et al.
JAMA 2008;300:173-181.
ABSTRACT | FULL TEXT  

Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
Wako et al.
J. Clin. Pathol. 2008;61:448-454.
ABSTRACT | FULL TEXT  

Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era
Shimizu et al.
Jpn J Clin Oncol 2007;0:hym105v1-12.
ABSTRACT | FULL TEXT  

A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer
Walz et al.
JCO 2007;25:3576-3581.
ABSTRACT | FULL TEXT  

Assessing Individual Risk for Prostate Cancer
Nam et al.
JCO 2007;25:3582-3588.
ABSTRACT | FULL TEXT  

A molecular correlate to the Gleason grading system for prostate adenocarcinoma
True et al.
Proc. Natl. Acad. Sci. USA 2006;103:10991-10996.
ABSTRACT | FULL TEXT  

The Effectiveness of Screening for Prostate Cancer: A Nested Case-Control Study
Concato et al.
Arch Intern Med 2006;166:38-43.
ABSTRACT | FULL TEXT  

Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy
Zakian et al.
Radiology 2005;234:804-814.
ABSTRACT | FULL TEXT  

Gonadotropin-releasing hormone and its receptor in normal and malignant cells
Harrison et al.
Endocr Relat Cancer 2004;11:725-748.
ABSTRACT | FULL TEXT  

Natural History of Early Localized Prostate Cancer
Osborn and Chodak
JAMA 2004;292:1549-1549.
FULL TEXT  

Preference Assessment Method Affects Decision-Analytic Recommendations: A Prostate Cancer Treatment Example
Elkin et al.
Med Decis Making 2004;24:504-510.
ABSTRACT  

Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 2004;96:1358-1367.
ABSTRACT | FULL TEXT  

Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening
Smith et al.
Arch Intern Med 2004;164:1227-1230.
ABSTRACT | FULL TEXT  

Natural History of Early, Localized Prostate Cancer
Johansson et al.
JAMA 2004;291:2713-2719.
ABSTRACT | FULL TEXT  

Racial Differences in Survival Among Men With Prostate Cancer and Comorbidity at Time of Diagnosis
Freeman et al.
AJPH 2004;94:803-808.
ABSTRACT | FULL TEXT  

Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era
Carter et al.
JCO 2003;21:4001-4008.
ABSTRACT | FULL TEXT  

Stage at Diagnosis and Survival in a Multiethnic Cohort of Prostate Cancer Patients
Oakley-Girvan et al.
AJPH 2003;93:1753-1759.
ABSTRACT | FULL TEXT  

Prostate cancer management: (1) an update on localised disease
Bott et al.
Postgrad. Med. J. 2003;79:575-580.
ABSTRACT | FULL TEXT  

Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?
Alibhai et al.
JCO 2003;21:3318-3327.
ABSTRACT | FULL TEXT  

Critical Review of Complementary Therapies for Prostate Cancer
Wilkinson and Chodak
JCO 2003;21:2199-2210.
ABSTRACT | FULL TEXT  

Radical prostatectomy as treatment for prostate cancer
Jewett et al.
CMAJ 2003;168:44-45.
FULL TEXT  

Curcumin (Diferuloyl-Methane) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in LNCaP Prostate Cancer Cells
Deeb et al.
Molecular Cancer Therapeutics 2003;2:95-103.
ABSTRACT | FULL TEXT  

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT | FULL TEXT  

Comparison of 2 Methods for Calculating Adjusted Survival Curves From Proportional Hazards Models
Ghali et al.
JAMA 2001;286:1494-1497.
ABSTRACT | FULL TEXT  

Prostate Cancer: Contrast-enhanced US for Detection
Halpern et al.
Radiology 2001;219:219-225.
ABSTRACT | FULL TEXT  

Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features
Alers et al.
Am. J. Pathol. 2001;158:399-406.
ABSTRACT | FULL TEXT  

Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer
Fowler et al.
JAMA 2000;283:3217-3222.
ABSTRACT | FULL TEXT  

The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:977-983.
ABSTRACT | FULL TEXT  

The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Grover et al.
CMAJ 2000;162:987-992.
ABSTRACT | FULL TEXT  

Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen
Nam et al.
JCO 2000;18:1036-1036.
ABSTRACT | FULL TEXT  

Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study
Potosky et al.
JNCI J Natl Cancer Inst 1999;91:1719-1724.
FULL TEXT  

Geriatrics and the Limits of Modern Medicine
Goodwin
NEJM 1999;340:1283-1285.
FULL TEXT  

Improving Appropriate Selection of Radical Prostatectomy for Prostate Cancer
Lewis and Rising
Eval Health Prof 1998;21:429-441.
ABSTRACT  

The Danger of Applying Group-level Utilities in Decision Analyses of the Treatment of Localized Prostate Cancer in Individual Patients
Cowen et al.
Med Decis Making 1998;18:376-380.
ABSTRACT  

Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 1998;280:975-980.
ABSTRACT | FULL TEXT  

Screening for prostate cancer
Hrouda et al.
BMJ 1998;316:1903a-1903.
FULL TEXT  

Detection of Early Prostate Cancer: Serendipitous or Systematic?
Iczkowski et al.
JAMA 1998;279:1439-1441.
FULL TEXT  

Starting Insulin Therapy in Patients With Type 2 Diabetes: Effectiveness, Complications, and Resource Utilization
Hayward et al.
JAMA 1997;278:1663-1669.
ABSTRACT  

Fifteen-Year Survival in Prostate Cancer: A Prospective, Population-Based Study in Sweden
Johansson et al.
JAMA 1997;277:467-471.
ABSTRACT  

Prostatectomy and Survival Among Men With Clinically Localized Prostate Cancer
Fryback et al.
JAMA 1996;276:1723-1724.
ABSTRACT  

Results of Radical Prostatectomy in Men With Clinically Localized Prostate Cancer: Multi-institutional Pooled Analysis
Gerber et al.
JAMA 1996;276:615-619.
ABSTRACT  

Urology
Albertsen
JAMA 1996;275:1857-1858.
ABSTRACT  

Questions about the Value of Early Intervention
Welch
NEJM 1996;334:1472-1473.
FULL TEXT  

Survival and Conservative Treatment for Localized Prostate Cancer
Swanson
JAMA 1996;275:31-31.
ABSTRACT  

Survival and Conservative Treatment for Localized Prostate Cancer
Cowen et al.
JAMA 1996;275:31-32.
ABSTRACT  

Screening for Prostate Cancer with Prostate-Specific Antigen -- An Examination of the Evidence
Woolf
NEJM 1995;333:1401-1405.
FULL TEXT